BCX9930
BCX9930-211
Phase 2 small_molecule terminated
Quick answer
BCX9930 for Complement 3 Glomerulopathy is a Phase 2 program (small_molecule) at BIOCRYST PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BIOCRYST PHARMACEUTICALS INC
- Indication
- Complement 3 Glomerulopathy
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated